Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $205.00 price target on Moderna (NASDAQ: MRNA) after the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE